Today, Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG). Read more HERE.
Day One Announces Updated FIREFLY-1 Data for Tovorafenib
Comments